ROBO1 and pancreatic neoplasm: In a study by Xia et al., anti-Roundabout Guidance Receptor 1 (ROBO1) CAR NK-92 cells were tested in combination with brachytherapy in an orthotopic pancreatic tumor model, leading to superior outcomes compared to brachytherapy alone.